

## Literatura ACTA MEDICINAE 4/2017 Gynekologie

- 2 **Apendektomie při indikaci laparoskopie pro syndrom chronické pánevní bolesti**  
MUDr. Denis Berezovskiy | MUDr. Pavel Vlasák | doc. MUDr. Zdeněk Novotný, CSc.  
Gynekologicko-porodnická klinika LF UK a FN Plzeň
- 2 **Komplikace operační léčby karcinomu prsu**  
doc. MUDr. David Pavlišta, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha
- 2 **Fertilitu zachovávající léčba u karcinomu endometria**  
MUDr. Josef Tihlařík | doc. MUDr. Jiří Bouda, Ph.D. | MUDr. Pavel Vlasák | MUDr. Jan Kostun | MUDr. Jiří Presl, Ph.D.  
Gynekologicko-porodnická klinika LF UK a FN Plzeň
- 3 **Co přinesla první dekáda primární prevence HPV asociovaných lézí?**  
doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 2. LF UK a FN Motol Praha
- 3 **Terapie vulvovaginálních kandidóz**  
doc. MUDr. Ivana Kuklová, CSc. Dermatovenerologická klinika 1. LF UK a VFN, Praha
- 4 **Suplementace kalcie a vitamínem D v prevenci a léčbě osteoporózy**  
MUDr. Olga Růžičková Revmatologický ústav, Praha
- 4 **Hyperandrogenní syndrom**  
MUDr. Eliška Rinnová | MUDr. Martin Smažinka Gynekologicko-porodnická klinika FN Plzeň
- 4 **Ileus u pacientky ve druhém trimestru těhotenství s pooperačními komplikacemi – kazuistika**  
MUDr. Lenka Paymová | MUDr. Jaroslava Karbanová Gynekologicko-porodnická klinika LF UK a FN Plzeň
- 4 **Hyperandrogenní stavy v gynekologii – kazuistika**  
MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě, Praha
- 5 **Využití fosfomycinu v terapii infekcí dolních cest močových**  
doc. MUDr. Jan Krhut, Ph.D. Urologické oddělení FN Ostrava, Katedra chirurgických oborů LF OU, Ostrava
- 5 **Aktuální farmakologická léčba hyperaktivního měchýře**  
MUDr. Oldřich Šottner Gynekologicko porodnická a urogynekologická ambulance na Vysočině, Gynekologicko-porodnická klinika 1. LF UK a Nemocnice Na Bulovce, Praha
- 5 **Laktobacily a kyselina mléčná: obnova přirozeného vaginálního prostředí jako klíčový faktor při léčbě vaginálních infekcí**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 6 **Bisfenoly A a S a jejich efekt na reprodukci**  
Ing. Tereza Žalmanová, Ph.D. | Ing. Kristýna Hošková, Ph.D. Fakulta agrobiologie, potravinových a přírodních zdrojů České zemědělské univerzity, Praha  
Ing. Jan Nevorál, Ph.D. Lékařská fakulta Univerzity Karlovy v Plzni  
Ing. Šárka Prokešová Fakulta agrobiologie, potravinových a přírodních zdrojů České zemědělské univerzity, Praha  
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha
- 7 **Kyselina acetylsalicylová a clopidogrel – klasický základ protidestičkové léčby**  
prof. MUDr. Jan Vojáček, DrSc., FESC, FACC I. interní kardiologická klinika LF UK a FN, Hradec Králové
- 7 **Fixní kombinaceazelastinu a fluticason propionátu – lékový profil**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 7 **Onkolytické viry při léčbě nádorových onemocnění**  
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha
- 7 **Perspektivy genové terapie Alzheimerovy choroby**  
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

# Apendektomie při indikaci laparoskopie pro syndrom chronické pánevní bolesti

MUDr. Denis Berezovskiy | MUDr. Pavel Vlasák | doc. MUDr. Zdeněk Novotný, CSc.

Gynekologicko-porodnická klinika LF UK a FN Plzeň

- 1 Reiter, R. C.: A profile of women with chronic pelvic pain. *Clin Obstet Gynecol*, 1990, 33, s. 130.
- 2 Farquhar, C. M. – Steiner, C. A.: Hysterectomy rates in the United States 1990–1997. *Obstet Gynecol*, 2002, 99, s. 229.
- 3 Howard, F. M.: The role of laparoscopy in chronic pelvic pain: promise and pitfalls. *Obstet Gynecol Surv*, 1993, 48, s. 357.
- 4 Bhattacharya, K. – Semm, K.: A laparoscopic crusader. *J Minim Access Surg*, 2007, 3, s. 35–36.
- 5 Lothar, W. – Popp, M. D.: Gynecologically indicated single-endoscopic laparoscopic appendectomy. *J Am Assoc Gynecol Laparosc*, 1998, 5, s. 275–281.
- 6 Yevgeny Shuhatovich, D. O. – Kurt, E. R. – McBurney, C.: Laparoscopic appendectomy experience with early operative interference in cases of disease of the vermiform appendix. *New York Med J*, 1889, 50, s. 676–684.
- 7 Zondervan, K. T. – Yudkin, P. L. – Vessey, M. P., et al.: Patterns of diagnosis and referral in women consulting for chronic pelvic pain in UK primary care. *Br J Obstet Gynaecol*, 1999, 106, s. 1156.
- 8 Howard, F. M.: The role of laparoscopy in the evaluation of chronic pelvic pain: pitfalls with a negative laparoscopy. *J Am Assoc Gynecol Laparosc*, 1996, 4, s. 85.
- 9 Trautmann, G. M. – Kip, K. E. – Richter, H. E., et al.: Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease? *Am J Obstet Gynecol*, 2008, 198, s. 30.
- 10 *Guidelines for diagnosis, treatment, and use of laparoscopy for surgical problems during pregnancy. Practice/clinical guidelines*. Publikováno v lednu 2011 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES).
- 11 Stany, M. P.: Laparoskopický přístup při řešení adnálních nálezů v graviditě. *Gynekologie po pramoci*, 2008, 3.
- 12 Kolařík, D. – Halaška, M. – Feyerreis, J.: *Repertorium gynekologie*. Maxdorf, Jessenius, Praha, 2011, s. 571.
- 13 Mangram, A. J. – Horan, T. C. – Pearson, M. L., et al.: Guideline for prevention of surgical site infection. *Am J Inf Cont*, 1999, 27, s. 97–134.

## Komplikace operační léčby karcinomu prsu

doc. MUDr. David Pavlišta, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

- 1 Pavlišta, D. – Dušková, M. – Novotný, J., et al.: Complications of axillary dissection in breast carcinoma. *Ceska Gynekol*, 2002, 67, s. 333–337.
- 2 van Bommel, A. J. – van de Velde, C. J. – Schmitz, R. F., et al.: Prevention of seroma formation after axillary dissection in breast cancer: a systematic review. *Eur J Surg Oncol*, 2011, 37, s. 829–835, doi: 10.1016/j.ejso.2011.04.012.
- 3 Robertson, S. A. – Jeevaratnam, J. A. – Agrawal, A., et al.: Mastectomy skin flap necrosis: challenges and solutions. *Breast Cancer*, 2017, 9, s. 141–152, doi: 10.2147/BCTT.S81712.
- 4 Platt, R. – Zucker, J. R. – Zaleznik, D. F., et al.: Perioperative antibiotic prophylaxis and wound infection following breast surgery. *J Anti-microb Chemother*, 1993, 31, s. 43–48.
- 5 Soares, E. W. – Nagai, H. M. – Bredt, L. C., et al.: Morbidity after conventional dissection of axillary lymph nodes in breast cancer patients. *World J Surg Oncol*, 2014, 12, s. 67, doi: 10.1186/1477-7819-12-67.
- 6 Salmon, R. J. – Ansquer, Y. – Asselain, B.: Preservation versus section of intercostal-brachial nerve (IBN) in axillary dissection for breast cancer – a prospective randomized trial. *Eur J Surg Oncol*, 1998, 24, s. 158–161.
- 7 Schuitevoerder, D. – White, I. – Fortino, J., et al.: Axillary web syndrome: an underappreciated complication of sentinel node biopsy in melanoma. *Am J Surg*, 2016, 211, s. 846–849, doi: 10.1016/j.amjsurg.2016.01.004.
- 8 Hafli, T. F. – Cohen, L. – Katz, J., et al.: Physical and psychological morbidity after axillary lymph node dissection for breast cancer. *J Clin Oncol*, 1999, 17, s. 143–149.
- 9 Kakada, J. T. – Stuntz, M. – Trivedi V., et al.: Objective assessment of axillary morbidity in breast cancer treatment. *Am Surg*, 1999, 65, s. 995–998.

## Fertilitu zachovávající léčba u karcinomu endometria

MUDr. Josef Tihlařík | doc. MUDr. Jiří Bouda, Ph.D. | MUDr. Pavel Vlasák |

MUDr. Jan Kostun | MUDr. Jiří Presl, Ph.D. Gynekologicko-porodnická klinika LF UK a FN Plzeň

- 1 Epidemiologie zhoubných nádorů v České republice [online]. Vyhledáno 10. 4. 2017, dostupné z: <http://www.svod.cz/>.
- 2 Brinton, L. A. – Berman, M. L. – Mortel, R., et al.: Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. *Am J Obstet Gynecol*, 1992, 167, s. 1317.
- 3 Barakat, R. R. – Park, R. C. – Grigsby, P. W., et al.: Corpus: epithelial tumors. In: Hoskins, W. H. – Perez, C. A. – Young, R. C. (eds.): *Principles and practice of gynecologic oncology*. Lippincott-Raven Publishers, Philadelphia, 1997, s. 859.
- 4 American College of Obstetricians and Gynecologists Committee on Gynecologic Practice: Tamoxifen and endometrial Cancer. *Committee opinion 232*. ACOG 2000, Washington, D.C.
- 5 Horn-Ross, P. L. – John, E. M. – Canchola, A. J., et al.: Phytoestrogen intake and endometrial cancer risk. *J Natl Cancer Inst*, 2003, 95, s. 1158.
- 6 Unfer, V. – Casini, M. L. – Costabile, L., et al.: Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. *Fertil Steril*, 2004, 82, s. 145.
- 7 Bandera, E. V. – Williams, M. G. – Sima, C., et al.: Phytoestrogen consumption and endometrial cancer risk: a population-based case-control study in New Jersey. *Cancer Causes Control*, 2009, 20, s. 1117.
- 8 Ollberding, N. J. – Lim, U. – Wilkens, L. R., et al.: Legume, soy, tofu, and isoflavone intake and endometrial cancer risk in postmenopausal women in the multiethnic cohort study. *J Natl Cancer Inst*, 2012, 104, s. 67.
- 9 Pottschman, N. – Swanson, C. A. – Siiteri, P., et al.: Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. *J Natl Cancer Inst*, 1996, 88, s. 756.
- 10 Amant, F. – Moerman, P. – Neven, P., et al.: Endometrial cancer. *Lancet*, 2005, 366, s. 491.
- 11 Lauby-Secretan, B. – Scoccianti, C. – Loomis, D., et al.: Body fatness and cancer – viewpoint of the IARC Working Group. *N Engl J Med*, 2016, 375, s. 794.
- 12 Berek, J. S. – Hacker, N. F.: Nonepithelial ovarian and fallopian tube cancers. In: Berek, J. S. – Hacker, N. F. (eds.): *Practical Gynecologic Oncology*, Lippincott Williams & Wilkins, Philadelphia, 2000, s. 539.
- 13 Schumel, S. T. – Cannistra, S. A.: Granulosa cell tumor of the ovary. *J Clin Oncol*, 2003, 21, s. 1180.
- 14 Zagnolo, V. – Pasinetti, B. – Sartori, E.: Clinical review of 63 cases of sex cord stromal tumors. *Eur J Gynaecol Oncol*, 2004, 25, s. 431.
- 15 Ollikainen, M. – Abdel-Rahman, W. M. – Moksso, A. L., et al.: Molecular analysis of familial colorectal carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? *J Clin Oncol*, 2005, 23, s. 4609.
- 16 Lucenteforte, E. – Talamini, R. – Montella, M., et al.: Family history of cancer and the risk of endometrial cancer. *Eur J Cancer Prev*, 2009, 18, s. 95.
- 17 Sandles, L. G. – Shulman, L. P. – Elias, S., et al.: Endometrial adenocarcinoma: genetic analysis suggesting heritable site-specific uterine cancer. *Gynecol Oncol*, 1992, 47, s. 167.
- 18 Mucci, L. A. – Hjelmberg, J. B. – Hartus, J. R., et al.: Familial risk and heritability of cancer among twins in nordic countries. *JAMA*, 2016, 315, s. 68.
- 19 Ollberding, N. J. – Lim, U. – Wilkens, L. R., et al.: Legume, soy, tofu, and isoflavone intake and endometrial cancer risk in postmenopausal women in the multiethnic cohort study. *J Natl Cancer Inst*, 2012, 104, s. 67.
- 20 North American Menopause Society. The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). *Menopause*, 2011, 18, s. 732.
- 21 Barakat, R. R. – Wong, G. – Kurtin, J. P., et al.: Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. *Gynecol Oncol*, 1994, 55, s. 164.
- 22 Myung, S. K. – Ju, W. – Choi, H. J., et al.: Soy intake and risk of endocrine-related gynaecological cancer: a meta-analysis. *BJOG*, 2009, 116, s. 1697.
- 23 Collaborative Group on Epidemiological Studies on Endometrial Cancer: Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. *Lancet Oncol*, 2015, 16, s. 1061.
- 24 American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. *Obstet Gynecol*, 2005, 106, s. 413.
- 25 Kimura, T. – Kamiura, S. – Yamamoto, T., et al.: Abnormal uterine bleeding and prognosis of endometrial cancer. *Int J Gynaecol Obstet*, 2004, 85, s. 145.
- 26 Seebacher, V. – Schmidt, M. – Polterauer, S., et al.: The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study. *BMC Cancer*, 2009, 9, s. 460.
- 27 Wright, T. C. Jr. – Massad, L. S. – Dunton, C. J., et al.: 2006 consensus guidelines for the management of women with abnormal cervical screening tests. *J Low Genit Tract Dis*, 2007, 11, s. 201.
- 28 Eltabbakh, G. H. – Shamonki, J. – Mount, S. L.: Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumor. *Gynecol Oncol*, 2005, 99, s. 309.
- 29 Leitao, M. M. Jr. – Kehoe, S. – Barakat, R. R., et al.: Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. *Gynecol Oncol*, 2009, 113, s. 105.
- 30 Montz, F. J. – Bristow, R. E. – Bovicelli, A., et al.: Intrauterine progesterone treatment of early endometrial cancer. *Am J Obstet Gynecol*, 2002, 186, s. 651.
- 31 Dhar, K. K. – Needhirajan, T. – Koslowski, M., et al.: Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. *Gynecol Oncol*, 2005, 97, s. 924.
- 32 Jadoul, P. – Donnez, J.: Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. *Fertil Steril*, 2003, 80, s. 1315.

- 33 Kinkel, K. – Kaji, Y. – Yu, K. K., et al.: Radiologic staging in patients with endometrial cancer: a meta-analysis. *Radiology*, 1999, 212, s. 711.
- 34 Gallos, I. D. – Yap, J. – Rajkhowa, M., et al.: Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. *Am J Obstet Gynecol*, 2012, 207, s. 266.
- 35 Park, J. Y. – Kim, D. Y. – Kim, J. H., et al.: Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). *Eur J Cancer*, 2013, 49, s. 868.

## Co přinesla první dekáda primární prevence HPV asociovaných lézí?

doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 2. LF UK a FN Motol Praha

- 1 European Centre for Disease Prevention and Control. *Introduction of HPV vaccines in EU countries – an update*. Stockholm, ECDC, 2012.
- 2 Fait, T. – Dvořák, V. – Skřivánek, A., et al.: Epidemiologie genitálních bradavic mezi ženami v České republice. *Čes Gynek*, 2012, 77, 4, s. 360–363.
- 3 Fenton, K. A. – Lowndes, C. M.: Recent trends in the epidemiology of STI in the European Union. *Sex Trans Infect*, 2004, 80, s. 255–263.
- 4 Desai, S. – Wetten, S. – Woodhall, S. C., et al.: Genital warts and cost of care in England. *Sex Trans Infect*, 2011, 87, s. 464–468.
- 5 Garland, S. M. – Hernandez-Avila, M. – Wheeler, C. M., et al.: Quadrivalent vaccine against human papillomavirus to prevent anogenital disease. *NEJM*, 2007, 356, s. 1928–1943.
- 6 Fairley, C. K. – Hocking, J. S. – Gurrin, L. C., et al.: Rapid decline in presentation of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. *Sex Transm Infect*, 2009, 85, s. 499–502.
- 7 Gerti, D. M. – Brotherton, J. M. – Seville, M.: Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. *Sex Health*, 2011, 8, s. 171–178.
- 8 Gallagher, T. Q. – Derkay, C. S.: Recurrent respiratory papillomatosis. *Curr Opin Otolaryngol Head Neck Surg*, 2008, 16, s. 645–655.
- 9 Dubová, J. – Vydrová, J. – Bendová, O., et al.: Výsledky vakcinace proti HPV u pacientů s rekurentní papilomatózou hrtanu. *Prostrad Med*, 2012, 13, s. 921–923.
- 10 D'Sousa, G. – Kreimer, A. – Viscidi, R., et al.: Case-control study of human papillomavirus and oropharyngeal cancer. *NEJM*, 2007, 356, s. 1944–1956.
- 11 Gillison, M. L. – Broutian, T. – Pickard, R. K., et al.: Prevalence of oral HPV infection in the United States, 2009–2010. *JAMA*, 2012, 307, s. 693–703.
- 12 Giuliano, A. R. – Palefsky, J. M. – Goldstone, S., et al.: Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. *N Engl J Med*, 2011, 364, s. 401–411.
- 13 Palefsky, J. M. – Giuliano, A. R. – Goldstone, S., et al.: HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med*, 2011, 365, s. 1567–1585.
- 14 Fait, T. – Pilka, R. – Dvořák, V.: Nonavalentní HPV vakcína – nová generace očkování proti HPV. *Ces Gynek*, 2015, 80, s. 397–400.
- 15 Donova, B. – Francin, N. – Guy, R., et al.: Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. *Lancet Infect Dis*, 2011, 11, s. 39–44.
- 16 Read, T. R. – Hocking, J. S. – Chen, M. Y., et al.: The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. *Sex Transm Infect*, 2011, 87, s. 544–547.
- 17 Dominiak-Felden, G. – Honbo, C. – Simondon, F.: Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: a cohort study. *PLoS One*, 2015, 10, s. e0132404.
- 18 Leval, A. – Herweijer, E. – Arnheim-Dahlström, L., et al.: Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. *J Infect Dis*, 2012, 206, s. 860–866.
- 19 Bauer, H. M. – Wright, G. – Chow, J.: Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007–2010. *Am J Public Health*, 2012, 102, s. 833–835.
- 17 Brotherton, J. M. – Fridman, M. – May, C. L., et al.: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. *Lancet*, 2011, 377, s. 2085–2092.
- 18 Powell, S. E. – Hariri, S. – Steinau, M., et al.: Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. *Vaccine*, 2012, 31, s. 109–113.
- 19 Gerti, D. M. – Brotherton, J. M. – Budd, A. C., et al.: Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. *BMC Med*, 2013, 11, s. 227.
- 20 Baldur-Felskov, B. – Dehlendorf, C. – Junge, J., et al.: Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. *Cancer Causes Control*, 2014, 25, s. 915–922.
- 21 Crowe, E. – Pandeya, N. – Brotherton, J. M., et al.: Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. *BMJ*, 2014, 348, s. g1458.
- 22 Mahmud, S. M. – Kliever, E. V. – Lambert, P., et al.: Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada. *J Clin Oncol*, 2014, 32, s. 438–443.
- 23 Smith, L. M. – Strumpf, E. C. – Kaufman, J. S., et al.: The early benefits of human papillomavirus vaccination on cervical dysplasia and genital warts. *Pediatrics*, 2015, 135, s. e1131–e1140.
- 24 Hariri, S. – Bennett, N. M. – Niccolai, L. M., et al.: Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States–2008–2012. *Vaccine*, 2015, 33, s. 1608–1613.
- 25 Herweijer, E. – Sundström, K. – Ploner, A., et al.: Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: a population-based study. *Int J Cancer*, 2016, 138, s. 2867–2874.
- 26 Tabrizi, S. N. – Brotherton, J. M. – Kaldor, J. M., et al.: Fall in human papillomavirus prevalence following a national vaccination program. *J Infect Dis*, 2012, 206, s. 1645–1651.
- 27 Markowitz, L. E. – Hariri, S. – Lin, C., et al.: Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. *J Infect Dis*, 2013, 208, s. 385–393.
- 28 Deleré, Y. – Remschmidt, C. – Leuschner, J., et al.: Human papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. *BMC Infect Dis*, 2014, 14, s. 87, doi: 10.1186/1471-2334-14-87.
- 29 Markowitz, L. E. – Liu, G. – Hariri, S., et al.: Prevalence of HPV after introduction of the vaccination program in the United States. *Pediatrics*, 2016, 137, s. 1–9.

## Terapie vulvovaginálních kandidóz

doc. MUDr. Ivana Kuklová, CSc. Dermatovenerologická klinika 1. LF UK a VFN, Praha

- 1 Workowski, K. A. – Bolan, G. A.: Centers for disease control and prevention. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep*, 2015, 64, s. 1.
- 2 Tibaldi, C. – Cappello, N. – Latino, M. A., et al.: Vaginal and endocervical microorganisms in symptomatic and asymptomatic non-pregnant females: risk factors and rates of occurrence. *Clin Microbiol Infect*, 2009, 15, s. 670.
- 3 Sobel, J. D.: Vulvovaginal candidosis. *Lancet*, 2007, 369, s. 1961.
- 4 Vermitsky, J. P. – Self, M. J. – Chadwick, S. G., et al.: Survey of vaginal-flora *Candida* species isolates from women of different age groups by use of species-specific PCR detection. *J Clin Microbiol*, 2008, 46, s. 1501.
- 5 Berthold, M. E. – Stafford, M. J.: Colonization of *Candida albicans* in vagina, rectum, and mouth. *J Fam Pract*, 1983, 16, s. 919.
- 6 Sobel, J. D. – Faro, S. – Force, R. W., et al.: Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. *Am J Obstet Gynecol*, 1998, 178, s. 203.
- 7 Horák, P.: Vulvovaginální kandidóza, farmakoterapie a prevence. *Prakt Lékař*, 2011, 7, s. 80–84.
- 8 Houang, E. T. – Chappatte, O. – Byrne, D., et al.: Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. *Antimicrob Agents Chemother*, 1990, 34, s. 909.
- 9 Pallas, P. G. – Kauffman, C. A. – Anders, D., et al.: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis*, 2009, 48, s. 503.
- 10 Sobel, J. D. – Chaim, W.: Treatment of *Torulopsis glabrata* vaginitis: retrospective review of boric acid therapy. *Clin Infect Dis*, 1997, 24, s. 649.
- 11 Sobel, J. D. – Chaim, W. – Nagappan, V., et al.: Treatment of vaginitis caused by *Candida glabrata*: use of topical boric acid and flucytosine. *Am J Obstet Gynecol*, 2003, 189, s. 1297.
- 12 Young, G. L. – Jewell, D.: Topical treatment for vaginal candidiasis (trush) in pregnancy. *Cochrane Database Syst Rev*, 2001, CD000225.
- 13 Howley, M. M. – Carter, T. C. – Browne, M. L., et al.: Fluconazole use and birth defects in the National Birth Defects Prevention Study. *Am J Obstet Gynecol*, 2016, 214, s. 657.e1.
- 14 Mending, W. – Brasch, J.: German Society for Gynecology and Obstetrics, et al.: Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. *Mycoses*, 2012, 55, suppl. 3, s. 1.
- 15 Sobel, J. D.: Management of patients with recurrent vulvovaginal candidiasis. *Drugs*, 2003, 63, s. 1059.
- 16 Patel, D. A. – Gillespie, B. – Sobel, J. D., et al.: Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: results of a prospective cohort study. *Am J Obstet Gynecol*, 2004, 190, s. 644.
- 17 Sobel, J. D. – Chaim, W.: Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. *J Clin Microbiol*, 1996, 34, s. 2497.
- 18 McClelland, R. S. – Richardson, B. A. – Hassan, W. M., et al.: Prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis. *J Infect Dis*, 2009, 199, s. 1883.
- 19 Sobel, J. D. – Wiesenfeld, H. C. – Martens, M., et al.: Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. *N Engl J Med*, 2004, 351, s. 876.
- 20 Pallas, P. G. – Kauffman, C. A. – Anders, D., et al.: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis*, 2009, 48, s. 503.
- 21 Danby, C. S. – Boikov, D. – Rautema-Richardson, R., et al.: Effect of pH on in vitro susceptibility of *Candida glabrata* and *Candida albicans* to 11 antifungal agents and implications for clinical use. *Antimicrob Agents Chemother*, 2012, 56, s. 1403.
- 22 Kuklová, I.: Kandidózy kůže a sliznic. *Čes Slov Derm*, 2015, 2, s. 47–53.

# Hyperandrogenní syndrom

MUDr. Eliška Rinnová | MUDr. Martin Smažinka Gynekologicko-porodnická klinika FN Plzeň

- 1 Pfeifer, S. M. – Kives, S.: Polycystic ovary syndrome in the adolescent. *Obstet Gynecol Clin North Am*, 2009, 36, s. 129–152.
- 2 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril*, 2004, 81, s. 19–25.
- 3 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod*, 2004, 19, s. 41–47.
- 4 Azziz, R. – Carmina, E. – Dewailly, D., et al.: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. *J Clin Endocrinol Metab*, 2006, 91, s. 4237–4245.
- 5 Hermann, D. A.: Polycystic ovary syndrome. *N Engl J Med*, 2005, 352, s. 1223–1236.
- 6 Carmina, E. – Oberfield, S. E. – Lobo, R. A.: The diagnosis of polycystic ovary syndrome in adolescents. *Am J Obstet Gynecol*, 2010, 203, s. e1–5.
- 7 Vrbíková, J. – Fanta, M. – Korytová, D.: *Syndrom polycystických ovarií*. Praha, Maxdorf, 2014, s. 8–68.
- 8 Adams, H.: *Practical pediatric and adolescent gynecology*. 2013, Wiley-Blackwell, New Jersey, US.
- 9 Emans, S. J. H. – Laufer, M. R. – Goldstein, D. P.: *Pediatric & adolescent gynecology*. 2005, Lippincott Williams & Wilkins.

## Ileus u pacientky ve druhém trimestru těhotenství s pooperačními komplikacemi – kazuistika

MUDr. Lenka Paymová | MUDr. Jaroslava Karbanová Gynekologicko-porodnická klinika LF UK a FN Plzeň

- 1 Perdue, P. W. – Johnson, H. W. – Stafford, P. W.: Intestinal obstruction complicating pregnancy. *Am J Surgery*, 1992, 164, s. 384–388.
- 2 Leyendecker, J. R. – Gorengaut, V. – Brown, J. J.: MR Imaging of Maternal Diseases of the Abdomen and Pelvis during Pregnancy and the Immediate Postpartum Period 1. *Radiographics*, 2004, 24, s. 1301–1316.
- 3 Hájek, Z. – Čech, E. – Maršál, K.: *Porodnictví*. Praha, Grada, 2014.
- 4 Roztočil, A.: *Moderní porodnictví*. Praha, Grada, 2008.
- 5 Zachariah, S. K. – Fenn, M. G.: Acute intestinal obstruction complicating pregnancy: diagnosis and surgical management. *BMJ case reports*, 2014, bcr2013203235.

## Hyperandrogenní stavy v gynekologii – kazuistika

MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě, Praha

- 1 Cordain, L. – Lindeberg, S. – Hurtado, M., et al.: Acne vulgaris: a disease of western civilization. *Arch Dermatol*, 2002, 138, s. 1584–1590.
- 2 Thiboutot, D. – Martin, P. – Volikos, L., et al.: Oxidative activity of the type 2 isozyme of 17 $\beta$ -hydroxysteroid dehydrogenase (17 $\beta$ -HSD) predominates in human sebaceous glands. *J Invest Dermatol*, 1998, 111, s. 390–395.
- 3 O'Connell, K. – Westhoff, C.: Pharmacology of hormonal contraceptives and acne. *Cutis*, 2008, 81, suppl. 1, s. 8–12.
- 4 Ferriman, D. – Gallwey, J. D.: Clinical assessment of body hair growth in women. *J Clin Endocrinol Metab*, 1961, 21, s. 1440.
- 5 Azziz, R. – Carmina, E. – Dewailly, D., et al.: The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. *Fertil Steril*, 2009, 91, s. 456–488.
- 6 Goodarzi, M. O. – Dumesic, D. A. – Chazenbalk, G., et al.: Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. *Nat Rev Endocrinol*, 2011, 7, s. 219–231.
- 7 Spritzer, P. – Billaud, L. – Thalabard, J. C., et al.: Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. *J Clin Endocrinol Metab*, 1990, 70, s. 642.
- 8 Birnbaum, M. D. – Rose, L. I.: The partial adrenocortical hydroxylase deficiency syndrome in infertile women. *Fertil Steril*, 1979, 32, s. 536.
- 9 Carmina, E. – Roseto, F. – Janni, A., et al.: Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. *J Clin Endocrinol Metab*, 2006, 91, s. 2.
- 10 Goldman, J. M. – Kapadia, L. J.: Virilization in a postmenopausal woman due to ovarian stromal hyperthecosis. *Postgrad Med J*, 1991, 67, s. 304.
- 11 Nagamani, M. – Lingold, J. C. – Gomez, L. G., et al.: Clinical and hormonal studies in hyperthecosis of the ovaries. *Fertil Steril*, 1981, 36, s. 326.

## Suplementace kalcíem a vitamínem D v prevenci a léčbě osteoporózy

MUDr. Olga Růžičková Revmatologický ústav, Praha

- 1 Blahoš, J.: Léčba osteoporózy. *Postgrad Med CZ*, 2002, 2, s. 211–215.
- 2 Eastell, R. – Watts, N. B. – Kelly, J. S.: Osteoporosis: consider the outcomes. Medscape: CME circle, 2001, dostupné z: www.medscape.com.
- 3 Papapoulos, S. E.: Pharmacologic management of osteoporosis; methodological issues, and results of intervention studies. Medscape: Women's health treatment updates, 2001, dostupné z: www.medscape.com.
- 4 Štěpán, J.: Otázky kolem osteoporózy. *Medica Revue*, 2001, 2, s. 15–20.
- 5 Cummings, S. R. – Kelsey, J. L. – Nevitt, M. C., et al.: Epidemiology of osteoporosis and osteoporotic fractures. *Epidemiol Rev*, 1985, 7, s. 178–208.
- 6 Francis, R. M. – Peacock, M. – Marshall, D. H., et al.: Spinal osteoporosis in men. *Bone Miner*, 1989, 5, s. 547–557.
- 7 Seman, E. – Melton, L. J. – Ofallon, W. M., et al.: Risk factors for spinal osteoporosis in men. *Am J Med*, 1983, 75, s. 977–983.
- 8 Kanis, J. – Johnell, O. – Gullberg, B., et al.: Risk factors for hip fracture in men from southern Europe: the MEDOS study. *Osteoporos Int*, 1999, 11, s. 153–157.
- 9 Broulík, P.: Příčiny a rizikové faktory osteoporózy. *Postgrad Med CZ*, 2002.
- 10 Bailie, S. P. – Davison, C. E. – Johnson, F. J., et al.: Pathogenesis of vertebral crush fractures in men. *Age Ageing*, 1992, 21, s. 139–141.
- 11 Dawson-Hughes, B., et al.: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *A Engl J Med*, 337, s. 670–676.
- 12 Matkovic, V. – Heaney, R. P.: Calcium balance during human growth: Evidence for threshold behavior. *Am J Clin Nutr*, 1992, 55, s. 992–996.
- 13 Dawson-Hughes, B. – Dallas, G. E. – Krall, E., et al.: A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. *N Engl J Med*, 1990, 323, s. 878–883.
- 14 Reid, R. – Ibbertson, H. K.: Calcium supplements in the prevention of steroid-induced osteoporosis. *Amer J Clin Nutr*, 1986, 44, s. 287–290.
- 15 Sambrook, P. – Birmingham, J. – Kelly, P., et al.: Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. *N Engl J Med*, 1995, 328, s. 1747–1752.
- 16 Adachi, J. D. – Ioannidis, G.: Calcium and vitamin D therapy in corticosteroid-induced bone loss: What is the evidence? *Calcif Tissue Int*, 1999, 65, s. 332–336.
- 17 Bouillon, R. – Van Schoor, N. M. – Gielen, E., et al.: Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. *J Clin Endocrinol Metab*, 2013, 98, s. 1283–1304.
- 18 Holick, M. F. – Binkley, N. C. – Bischoff-Ferrari, H. A., et al.: Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *The J Clin Endocrinol Metab*, 2011, 96, s. 1911–1930.
- 19 Adachi, J. D. – Ioannidis, G.: Calcium and vitamin D therapy in corticosteroid-induced bone loss: What is the evidence? *Calcif Tissue Int*, 1999, 65, s. 332–336.
- 20 Lund, B. – Andersen, R. B. – Trios, T., et al.: Effect of 1-alpha-hydroxy vitamin D<sub>3</sub> and 1,25-dihydroxy vitamin D<sub>3</sub> on intestine and bone in glucocorticoid-treated patients. *Clin Endocrinol*, 1977, 7, s. 177–181.
- 21 Ringe, J. D.: Active vitamin D metabolites in glucocorticoid-induced osteoporosis. *Calcif Tissue Int*, 1997, 60, s. 124–127.
- 22 Tsurukami, H. – Nakamura, T. – Suzuki, I. K., et al.: A novel synthetic vitamin D analogue, 2 $\beta$ -(3-hydroxypropoxy) 1,25-dihydroxyvitamin D<sub>3</sub> (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. *Calcif Tissue Int*, 1994, 54, s. 142–149.
- 23 Shiraiishi, A. – Takeda, S. – Masaki, T., et al.: Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. *J Bone Miner Res*, 2000, 15, s. 770–779.
- 24 Graf, H. – Tummvoll, H. K. – Kovarik, J. – Bergmann, H.: Aktive Vitamin-D-Metabolite in der Therapie der Cortisonosteoporose. *Wiener Klin Wschr*, 1980, 92, s. 776–777.
- 25 Braun, J. J. – Birkenhager-Frenkel, D. H. – Rietveld, A. H., et al.: Influence of lalpa-(OH) D<sub>3</sub> administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment;

- A double blind controlled study. *Clin Endocrinol*, 1983, 18, s. 265–273.
- 26 **Schaadt, O. P. – Bohr H. H.**: Alfacalcidol in prednisone treatment – A controlled study of effect on bone mineral content in lumbar spine, femoral neck and shaft. *Calcif Tissue Int*, 1986, 39, suppl. A58.
- 27 **Verstraeten, A. – Dequur, J. – Nijls, J., et al.**: Prevention of postmenopausal bone loss in rheumatoid arthritis patients. A two-year prospective study. *Clin Exp Rheumatol*, 1989, 7, s. 351–358.
- 28 **Yamada H.**: Long-term effect of alpha-hydroxy vitamin D, calcium and thiazide administration of glucocorticoid-induced osteoporosis. *Nippon Naibunpi Gakkai Zasshi*, 1989, 65, s. 603–614.
- 29 **Van Cleemput, J. – Daenen, W. – Geusens, P., et al.**: Prevention of bone loss in cardiac transplant recipients. *Transplantation*, 1996, 61, s. 1495–1499.
- 30 **Chapuy, M. C. – Arlot, M. E. – Duboef, F., et al.**: Vitamin D<sub>3</sub> and calcium to prevent hip fractures in elderly women. *N Engl J Med*, 1992, 327, s. 1637–1642.
- 31 **Dawson-Huges, B. – Hartus, S. S. – Krall, E. A., et al.**: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. *N Engl J Med*, 1997, 337, s. 670–676.
- 32 **Francis, R. M. – Boyle, I. T. – Moritz, C., et al.**: A comparison of the effects of alfacalcidol treatment and vitamin D<sub>3</sub> supplementation on calcium absorption in elderly women with vertebral fractures. *Osteoporos Int*, 1996, 6, s. 284–290.
- 33 **Bischoff-Ferrari, H. A. – Borchers, M. – Gudat, F., et al.**: Vitamin D receptor expression in human muscle tissue decreases with age. *J Bone Min Res*, 2004, s. 265–269.

## Využití fosfomycinu v terapii infekcí dolních cest močových

doc. MUDr. Jan Krhut, Ph.D. Urologické oddělení FN Ostrava, Katedra chirurgických oborů LF OU, Ostrava

- 1 **Hooton, T. C.**: Uncomplicated urinary tract infection. *N Engl J Med*, 2012, 366, s. 1028–1037.
- 2 **Wiedemann, B. – Heisig, A. – Heisig, P.**: Uncomplicated urinary tract infections and antibiotic resistance-epidemiological and mechanistic aspects. *Antibiotics* (Basel), 2014, 3, s. 341–352.
- 3 **Grabe, M. – Bartoletti, R. – Bjerklund-Johansen, T. E., et al.**: *Guidelines on Urological Infections*. European Association of Urology, 2014.
- 4 **Mazzei, T. – Cassetta, M. I. – Fallani, S., et al.**: Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. *Int J Antimicrob Agents*, 2006, 28, suppl, s. 35–41.
- 5 **Michalopoulos, A. S. – Livaditis, I. G. – Gougoutas, V.**: The revival of fosfomycin. *Int J Infect Dis*, 2011, 15, s. 732–739.
- 6 **Demir, T. – Buyukguclu, T.**: Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. *Int J Infect Dis*, 2013, 17, s. 966–970.
- 7 **Maraki, S. – Samonis, G. – Rafailidis, P. I., et al.**: Susceptibility of urinary tract bacteria to fosfomycin. *Antimicrob Agents Chemother*, 2009, 53, s. 4508–4510.
- 8 **Martin, D. – Fougnot, S. – Grobost, F., et al.**: Prevalence of extended-spectrum beta-lactamase producing *Escherichia coli* in community-onset urinary tract infections in France in 2013. *J Infect*, 2016, 72, s. 201–206.
- 9 **Qiao, L. D. – Zheng, B. – Chen, S., et al.**: Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. *BMJ Open*, 2013, 3, s. e004157.
- 10 **Wagenlehner, F. M. – Vahlensieck, W. – Bauer, H. W., et al.**: Prevention of recurrent urinary tract infections. *Minerva Urol Nefrol*, 2013, 65, s. 9–20.
- 11 **Rudenko, N. – Dorofeyev, A.**: Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin tromethamine. Double blind, randomized, parallel group, placebo controlled study. *Arzneimittelforschung*, 2005, 55, s. 420–427.
- 12 **Bookstaver, P. B. – Bland, C. M. – Griffin, B., et al.**: A review of antibiotic use in pregnancy. *Pharmacotherapy*, 2015, 35, s. 1052–1062.
- 13 **Kahlmeter, G. – Poulsen, H. O.**: Antimicrobial susceptibility of *Escherichia coli* from community-acquired urinary tract infections in Europe: the ECO-SENS study revisited. *Int J Antimicrob Agents*, 2012, 39, s. 45–51.

## Aktuální farmakologická léčba hyperaktivního měchýře

MUDr. Oldřich Šottner Gynekologicko porodnická a urogynekologická ambulance na Vysočině, Gynekologicko-porodnická klinika 1. LF UK a Nemocnice Na Bulovce, Praha

- 1 **Abrams, P. – Chapple, C. R. – Junemann, K. P., et al.**: Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome. *World J Urol*, 2012, 30, s. 385–392.
- 2 **Abrams, P. – Cardozo, L. – Fall, M., et al.**: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. *Neurourol Urodyn*, 2002, 21, s. 167–178.
- 3 **Cardozo, L. – Castro-Diaz, D. – Gittelmann, M., et al.**: Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. *Int Urogynecol J Pelvic Floor Dysfunct*, 2006, 17, s. 512–519.
- 4 **Cardozo, L.**: The overactive bladder syndrome: treating patients on an individual basis. *BJU Int*, 2007, 99, suppl. 3, s. 1–7.
- 5 **Cardozo, L. – Hessdorfer, E. – Milani, R., et al.**: Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. *BJU Int*, 2008, 102, s. 1120–1127.
- 6 **Cardozo, L. – Khullar, V. – Wang, J. T., et al.**: Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? *BJU Int*, 2010, 106, s. 816–821.
- 7 **Cardozo, L. D. – Van Kerrebroeck, P. E. – Staskin, D. R.**: Considerations for the management of urgency symptoms in patients with overactive bladder syndrome. *World J Urol*, 2009, 27, s. 755–763.
- 8 **Chapple, C. R. – Martinez-Garcia, R., et al.**: A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. *Eur Urol*, 2005, 48, s. 464–470.
- 9 **Chapple, C. R. – Cardozo, L. – Steers, W. D., et al.**: Solifenacin significantly improves all symptoms of overactive bladder syndrome. *Int J Clin Pract*, 2006, 60, s. 959–966.
- 10 **Hsiao, S. M. – Lin, H. H. – Kuo, H. C.**: Treatment outcome of overactive bladder patients receiving antimuscarinic therapy for more than one year. *Low Urin Tract Symptoms*, 12. 8. 2016, Epub před tiskem, doi: 10.1111/luts.12136.
- 11 **Juliato, C. R. – Baccaro, L. F. – Pedro, A. O., et al.**: Subjective urinary urgency in middle age women: A population-based study. *Maturitas*, 2016, 85, s. 82–87.
- 12 **López, R. H. – Torres, C. L. – Ponce, E. I., et al.**: Management of overactive bladder with onabotulinumtoxinA: Systematic review and meta-analysis. *Urology*, 2017, 100, s. 53–58.
- 13 **Marcelissen, T. A. – Rahnama'i, M. S. – Sniijkers, A., et al.**: Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms. *World J Urol*, 2017, 35, s. 307–311.
- 14 **Martan, A. – Masata, J. – Krhut, J., et al.**: Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study. *Eur J Obstet Gynecol Reprod Biol*, 2016, 210, s. 247–250.
- 15 **Milsom, I.**: Lower urinary tract symptoms in women. *Curr Opin Urol*, 2009, 19, s. 337–341.
- 16 **Rao, V. N. – Gopalakrishnan, G. – Saxena, A., et al.**: Nocturia – symptom or a disease? *J Assoc Physicians India*, 2016, 64, s. 56–63.
- 17 **Robinson, D. – Cardozo, L.**: The emerging role of solifenacin in the treatment of overactive bladder. *Expert Opin Investig Drugs*, 2004, 13, s. 1339–1348.
- 18 **Robinson, D. – Cardozo, L.**: Solifenacin in the management of the overactive bladder syndrome. *Int J Clin Pract*, 2005, 59, s. 1229–1236.
- 19 **Robinson, D. – Cardozo, L.**: Pharmacotherapy of overactive bladder syndrome. *Expert Rev Clin Pharmacol*, 2008, 1, s. 163–175.
- 20 **Robinson, D. – Cardozo, L.**: Solifenacin: pharmacology and clinical efficacy. *Expert Rev Clin Pharmacol*, 2009, 2, s. 239–253.
- 21 **Sand, P. K. – Johnson li, T. M. – Rovner, E. S., et al.**: Trosipium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged >= 75 years) with overactive bladder syndrome. *BJU Int*, 2011, 107, s. 612–620.
- 22 **Truzzi, J. C.**: Overactive bladder syndrome, detrusor overactivity and the botulinum toxin. *Rev Recent Clin Trials*, 2015, 10, s. 128–134.
- 23 **Vecchioli, S. C. – Morosetti, C.**: Comparison of therapeutic efficacy and urodynamic findings of solifenacin succinate versus mirabegron in women with overactive bladder syndrome: results of a randomized controlled study. *Urol Int*, 2016, 97, s. 325–329.
- 24 **Wagg, A. – Wyndaele, J. J. – Sieber, P.**: Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. *Am J Geriatr Pharmacother*, 2006, 4, s. 14–24.
- 25 **Wagg, A. – Majumdar, A. – Toozs-Hobson, P., et al.**: Current and future trends in the management of overactive bladder. *Int Urogynecol J Pelvic Floor Dysfunct*, 2007, 18, s. 81–94.
- 26 **Wagg, A. S. – Cardozo, L. – Chapple, C., et al.**: Overactive bladder syndrome in older people. *BJU Int*, 2007, 99, s. 502–509.

## Laktobacily a kyselina mléčná: obnova přirozeného vaginálního prostředí jako klíčový faktor při léčbě vaginálních infekcí

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 **Didaxi, T. – Mozaffari, S. – Nikfar, S., et al.**: Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. *World J Gastroenterol*, 2015, 21, s. 3072–3084.
- 2 **Lv, Z. – Wang, B. – Zhou, X., et al.**: Efficacy and safety of probiotics as adjuvant agents for *Helicobacter pylori* infection: A meta-analysis. *Exp Ther Med*, 2015, 9, s. 707–716.
- 3 **Hao, Q. – Dong, B. R. – Wu, T.**: Probiotics for preventing acute upper respiratory tract infections. *Cochrane Database Syst Rev*, 2015, 2, CD006895.
- 4 **Zuccotti, G. – Meneghin, F. – Acetin, A., et al.**: Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis. *Allergy*, 2015, 70, s. 1356–1371.
- 5 **Petricevic, L. – Unger, F. M. – Viersstein, H., et al.**: Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women. *Eur J Obstet Gynecol Reprod*

- Biol*, 2008, 141, s. 54–57.
- 6 Vujic, G. – Jajac, K. A. – Despot, S., et al.: Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study. *Eur J Obstet Gynecol Reprod Biol*, 2013, 168, s. 75–79.
  - 7 Oduyeb, O. O. – Anorlu, R. I. – Ogunsoola, F. T.: The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. *Cochrane Database Syst Rev*, 2009, CD006055.
  - 8 Marcone, V. – Calzolari, E. – Bertini, M.: Effectiveness of vaginal administration of Lactobacillus rhamnosus following conventional metronidazole therapy: how to lower the rate of bacterial vaginosis recurrences. *New Microbiol*, 2008, 31, s. 429–433.
  - 9 Reid, G.: Probiotic Lactobacilli for urogenital health in women. *J Clin Gastroenterol*, 2008, 42, suppl. 3, s. S234–S236.
  - 10 Anukam, K. C. – Osazuwa, E. – Osemene, G. I., et al.: Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. *Microbes Infect*, 2006, 8, s. 2772–2776.
  - 11 Anukam, K. – Osazuwa, E. – Ahonkhaj, I., et al.: Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. *Microbes Infect*, 2006, 8, s. 1450–1454.
  - 12 Czaja, C. A. – Stapleton, A. E. – Yarova-Yarova, Y., et al.: Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women. *Infect Dis Obstet Gynecol*, 2007, s. 35387.
  - 13 Larsson, P. G. – Stray-Pedersen, B. – Rytting, K. R., et al.: Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. *BMC Womens Health*, 2008, 8, s. 3.
  - 14 Mastromarino, P. – Macchia, S. – Meggiorini, L., et al.: Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. *Clin Microbiol Infect*, 2009, 15, s. 67–74.
  - 15 Hemmerling, A. – Harrison, W. – Schroeder, A., et al.: Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis. *Sex Transm Dis*, 2009, 36, s. 564–569.
  - 16 Rossi, A. – Rossi, T. – Bertini, M., et al.: The use of Lactobacillus rhamnosus in the therapy of bacterial vaginosis. Evaluation of clinical efficacy in a population of 40 women treated for 24 months. *Arch Gynecol Obstet*, 2010, 281, s. 1065–1069.
  - 17 Marcone, V. – Rocca, G. – Lichtner, M., et al.: Long-term vaginal administration of Lactobacillus rhamnosus as a complementary approach to management of bacterial vaginosis. *Int J Gynaecol Obstet*, 2010, 110, s. 223–226.
  - 18 Ya, W. – Reifer, C. – Miller, L. E.: Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study. *Am J Obstet Gynecol*, 2010, 203, s. 120–126.
  - 19 Barrons, R. – Tassone, D.: Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. *Clin Ther*, 2008, 30, s. 453–468.
  - 20 Senok, A. C. – Verstraelen, H. – Temmerman, M., et al.: Probiotics for the treatment of bacterial vaginosis. *Cochrane Database Syst Rev*, 2009, CD006289.
  - 21 Homayouni, A. – Bastani, P. – Ziyadi, S., et al.: Effects of probiotics on the recurrence of bacterial vaginosis: a review. *J Low Genit Tract Dis*, 2014, 18, s. 79–86.
  - 22 Huang, H. – Song, L. – Zhao, W.: Effects of probiotics for the treatment of bacterial vaginosis in adult women: a meta-analysis of randomized clinical trials. *Arch Gynecol Obstet*, 2014, 289, s. 1225–1234.
  - 23 Bolton, M. – van der Straten, A. – Cohen, C. R.: Probiotics: potential to prevent HIV and sexually transmitted infections in women. *Sex Transm Dis*, 2008, 35, s. 214–225.
  - 24 Martin, R. – Soberon, N. – Vazquez, F., et al.: Vaginal microbiota: composition, protective role, associated pathologies, and therapeutic perspectives. *Enferm Infect Microbiol Clin*, 2008, 26, s. 160–167.
  - 25 Timan, P. – Rojanasthien, N. – Manorot, M., et al.: Effect of synbiotic fermented milk on oral bioavailability of isoflavones in postmenopausal women. *Int J Food Sci Nutr*, 2014, 65, s. 761–767.
  - 26 Barreto, F. M. – Colado Simao, A. N. – Morimoto, H. K., et al.: Beneficial effects of Lactobacillus plantarum on glycemia and homocysteine levels in postmenopausal women with metabolic syndrome. *Nutrition*, 2014, 30, s. 939–942.
  - 27 Liang, M. T.: Probiotics: a critical review of their potential role as anti-hypertensives, immune modulators, hypocholesterolemic, and perimenopausal treatments. *Nutr Rev*, 2007, 65, s. 316–328.

## Bisfenoly A a S a jejich efekt na reprodukci

Ing. Tereza Žalmanová, Ph.D. | Ing. Kristýna Hošková, Ph.D.

Fakulta agrobiologie, potravinových a přírodních zdrojů České zemědělské univerzity, Praha

Ing. Jan Nevorál, Ph.D. Lékařská fakulta Univerzity Karlovy v Plzni

Ing. Šárka Prokešová Fakulta agrobiologie, potravinových a přírodních zdrojů

České zemědělské univerzity, Praha

prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

- 1 Colborn, T.: Endocrine disruption overview: Are males at risk? In: Baskin, L. S. (eds.): Hypospadias and genital development. *Advances in Experimental Medicine and Biology*. Springer, Boston, MA, 2004, 545, s. 189–201.
- 2 Halden, R. U.: Plastics and health risks. *An Rev Pub Health*, 2010, 31, s. 179–194.
- 3 Tatina, T. M. – Hauser, R. – Sathyanarayana, S., et al.: Exposure to endocrine-disrupting chemicals in the USA: a population-based disease burden and cost analysis. *Lancet Diabetes Endocrinology*, 2016, 4, s. 996–1003.
- 4 Skakkebaek, N. E. – Rajpert-De Mente, E. – Buck Louis, G. M., et al.: Male reproductive disorders and fertility trends: Influences of environment and genetic susceptibility. *Physiological Reviews*, 2016, 96, s. 55–97.
- 5 Hunt, P. A. – Sathyanarayana, S. – Fowler, P. A., et al.: Female reproductive disorders, diseases, and costs of exposure to endocrine disrupting chemicals in the European Union. *J Clin Endocrinol Metab*, 2016, 101, s. 1562–1570.
- 6 Trasande, L. – Zoeller, R. T. – Haas, U., et al.: Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European Union. *J Clin Endocrinol Metab*, 2015, 100, s. 1245–1255.
- 7 Bisphenol A (BPA) Joint Emerging Science Working Group: *Updated review of literature and data on bisphenol A (CASRN 80-05-7)*. Food and Drug Administration, 2014, s. 1–219.
- 8 EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF): Scientific Opinion on the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs: Executive summary. *EFSA Journal*, 2015, 13, s. 3978.
- 9 Rubin, B. S.: Bisphenol A: An endocrine disruptor with widespread exposure and multiple effects. *J Steroid Biochem Molecular Biology*, 2011, 127, s. 27–34.
- 10 Vandenberg, L. N. – Chahoud, I. – Heindel, J. J., et al.: Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A. *Env Health Perspect*, 2010, 118, s. 1055–1070.
- 11 Calafat, A. M. – Ye, X. – Wong, L.-Y., et al.: Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003–2004. *Env Health Perspect*, 2008, 116, s. 39–44.
- 12 Braun, J. M. – Kalkbrenner, A. E. – Calafat, A. M., et al.: Variability and predictors of urinary bisphenol A concentrations during pregnancy. *Env Health Perspect*, 2011, 119, s. 131–137.
- 13 Calafat, A. M. – Weuve, J. – Ye, X., et al.: Exposure to bisphenol A and other phenols in neonatal intensive care unit premature infants. *Env Health Perspect*, 2009, 117, s. 639–644.
- 14 Fu, P. – Kawamura, K.: Ubiquity of bisphenol A in the atmosphere. *Environmental Pollution*, 2010, 158, s. 3138–3143.
- 15 Watson, C. S. – Bulayeva, N. N. – Wozniak, A. L., et al.: Signaling from the membrane via membrane estrogen receptor- $\alpha$ : Estrogens, xenoestrogens, and phytoestrogens. *Steroids*, 2005, 70, s. 364–371.
- 16 Ben-Jonathan, N. – Steimetz, R.: Xenoestrogens: The emerging story of bisphenol A. *Trends Endocrinol Metab*, 1998, 9, s. 124–128.
- 17 Routledge, E. J. – White, R. – Parker, M. G., et al.: Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER)  $\alpha$  and ER $\beta$ . *J Biol Chem*, 2000, 275, s. 35986–35993.
- 18 Patisaul, H. B. – Fortino, A. L. – Polston, E. K.: Neonatal genistein or bisphenol-A exposure alters sexual differentiation of the AVPV. *Neurotoxicol Teratol*, 2006, 28, s. 111–118.
- 19 Johnson, S. A. – Javurek, A. B. – Painter, M. S., et al.: Disruption of parenting behaviors in California mice, a monogamous rodent species, by endocrine disrupting chemicals. *PLoS ONE*, 2015, 10, e0126284.
- 20 Heimleier, R. A. – Shi, Y.-B.: Amphibian metamorphosis as a model for studying endocrine disruption on vertebrate development: Effect of bisphenol A on thyroid hormone action. *Gen Compar Endocrinol*, 2010, 168, s. 181–189.
- 21 Prasanth, G. K. – Divya, L. M. – Sadasivan, C.: Bisphenol-A can bind to human glucocorticoid receptor as an agonist: an in silico study. *J App Toxicol*, 2010, 30, s. 769–774.
- 22 Bromer, J. G. – Zhou, Y. – Taylor, M. B., et al.: Bisphenol-A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen response. *FASEB Journal*, 2010, 24, s. 2273–2280.
- 23 Alonso-Magdalena, P. – Morimoto, S. – Ripoll, C., et al.: The estrogenic effect of bisphenol A disrupts pancreatic  $\beta$ -cell function in vivo and induces insulin resistance. *Env Health Perspect*, 2006, 114, s. 106–112.
- 24 Cabaton, N. J. – Wadia, P. R. – Rubin, B. S., et al.: Perinatal exposure to environmentally relevant levels of bisphenol A decreases fertility and fecundity in CD-1 mice. *Env Health Perspect*, 2011, 119, s. 547–552.
- 25 Ramos, J. G. – Varayoud, J. – Kass, L., et al.: Bisphenol A induces both transient and permanent histofunctional alterations of the hypothalamic-pituitary-gonadal axis in prenatally exposed male rats. *Endocrinol*, 2010, 144, s. 3206–3215.
- 26 Hunt, P. A. – Koehler, K. E. – Susiarjo, M., et al.: Bisphenol A exposure causes meiotic aneuploidy in the female mouse. *Current Biology*, 2003, 13, s. 546–553.
- 27 Markey, C. M. – Wadia, P. R. – Rubin, B. S., et al.: Long-term effects of fetal exposure to low doses of the xenoestrogen bisphenol-A in the female mouse genital tract. *Biol Rep*, 2005, 72, s. 1344–1351.
- 28 Vandenberg, L. N. – Maffini, M. V. – Wadia, P. R., et al.: Exposure to environmentally relevant doses of the xenoestrogen bisphenol-A alters development of the fetal mouse mammary gland. *Endocrinol*, 2007, 148, s. 116–127.
- 29 Sugiyama-Ogasawara, M. – Ozaki, Y. – Sonta, S., et al.: Exposure to bisphenol A is associated with recurrent miscarriage. *Human Reproduction*, 2005, 20, s. 2325–2329.
- 30 Cantonwine, D. – Meeker J. D. – Hu, H., et al.: Bisphenol A exposure in Mexico City and risk of prematurity: a pilot nested case control study. *Environmental Health*, 2010, 9, s. 62.
- 31 Mok-Lin, E. – Ehrlich, S. – Williams, P. L., et al.: Urinary bisphenol A concentrations and ovarian response among women undergoing IVF. *Int J Andrology*, 2010, 33, s. 385–393.
- 32 Yang, Y. J. – Hong, Y.-C. – Oh, S.-Y., et al.: Bisphenol A exposure is associated with oxidative stress and inflammation in postmenopausal women. *Env Research*, 2009, 109, s. 797–801.
- 33 Liao, C. – Fu, L. – Kannan, K.: Bisphenol S, a new bisphenol analogue, in paper products and currency bills and its association with bisphenol A residues. *Env Science Technol*, 2012, 46, s. 6860–6866.
- 34 Liao, C. – Liu, F. – Alomirah, H., et al.: Bisphenol S in urine from the United States and seven Asian countries: Occurrence and human exposures. *Env Sci Technol*, 2012, 46, s. 6860–6866.
- 35 Eladak, S. – Grisin, T. – Moison, D., et al.: A new chapter in the bisphenol A story: bisphenol S and bisphenol F are not safe alternatives to this compound. *Fertil Steril*, 2015, 103, s. 11–21.
- 36 Viñas, R. – Watson, C. S.: Bisphenol S disrupts estradiol-induced non-genomic signaling in a rat pituitary cell line: Effects on cell functions. *Env Health Perspect*, 2013, 121, s. 352–358.
- 37 Hong, S. – Kho, Y. – Choi, K.: Effects of bisphenol S exposure on endocrine functions and reproduction of zebrafish. *Env Sci Technol*, 2013, 47, s. 8793–8800.
- 38 Žalmanová, T. – Hošková, K. – Nevorál, J. – Adámková, K. – Kott, T. – Šulc, M. – Kotíková, Z. – Prokešová, Š. – Jílek, F. – Králíčková, M. – Petr, J.: Bisphenol S negatively affects the meiotic maturation of pig oocytes. *Scientific Reports*, 2017, 7, s. 485.
- 39 Viel, J.-F. – Warembourg, C. – Le Maner-Idrissi, G., et al.: Pyrethroid insecticide exposure and cognitive developmental disabilities in children: The PELAGIE mother-child cohort. *Env Intern*, 2015, 82, s. 69–75.
- 40 Petr, J. – Chmelíková, E. – Žalmanová, T., et al.: Pyrethroids cypermethrin, deltamethrin and fenvalerate have different effects on in vitro maturation of pig oocytes at different stages of growth. *Animal*, 2013, 7, s. 134–142.
- 41 Ji, K. – Hong, S. – Kho, Y. – Choi, K.: Effects of bisphenol S exposure on endocrine functions and reproduction of zebrafish. *Env Sci Technol*, 2013, 47, s. 8793–8800.

# Kyselina acetylsalicylová a clopidogrel – klasický základ protidestičkové léčby

prof. MUDr. Jan Vojáček, DrSc., FESC, FACC I. interní kardiologická klinika LF UK a FN, Hradec Králové

- 1 Halvorsen, S. – Andreotti, F. – ten Berg, J. M., et al.: Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. *J Am Coll Cardiol*, 2014, 64, s. 319–327.
- 2 Baigent, C. – Blackwell, L. – Collins, R., et al.: Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet*, 2009, 373, s. 1849–1860.
- 3 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. *Lancet*, 1988, 13, 2, s. 349–360 (autor neuveden).

## Fixní kombinace azelastinu a fluticason propionátu – lékový profil

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Bousquet, J. – Bachert, C. – Bernstein, J., et al.: Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. *Expert Opin Pharmacother*, 2015, 16, s. 913–928.
- 2 Derendorf, H. – Munzel, U. – Petzold, U., et al.: Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. *Br J Clin Pharmacol*, 2012, 74, s. 125–133.
- 3 Hampel, F. C. – Ratner, P. H. – Van, B. J., et al.: Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. *Ann Allergy Asthma Immunol*, 2010, 105, s. 168–173.
- 4 Carr, W. – Bernstein, J. – Lieberman, P., et al.: A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. *J Allergy Clin Immunol*, 2012, 129, s. 1282–1289.
- 5 Prenner, B. M.: A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US. *J Asthma Allergy*, 2016, 9, s. 135–143.
- 6 Klimek, L. – Bousquet, J. – Price, D.: Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis. *Expert Opin Drug Saf*, 2016, 15, s. 117–129.

## Onkolytické viry při léčbě nádorových onemocnění

prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

- 1 IMLYGIC (talimogene laherparepvec) Suspension for intralesional injection. Initial U.S. Approval. Food and Drug Administration, 2015.
- 2 European Medicines Agency decision P/0105/2016 of 15 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for talimogene laherparepvec (Imlygic), (EMA-001251-PIP01-11-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council.
- 3 Dock, G.: The influence of complicating diseases upon leukemia. *Am J Med Science*, 1904, 127, s. 563–592.
- 4 Levaditi, C. – Nicolau, S.: Vaccines et néoplasmes. *Annales de l'Institut Pasteur*, 1923, 37, s. 443–447.
- 5 Smith, R. R. – Huebner, R. J. – Rowe, W. P., et al.: Studies on the use of viruses in the treatment of carcinoma of the cervix. *Cancer*, 1956, 6, s. 1211–1218.
- 6 Asada, T.: Treatment of human cancer with mumps virus. *Cancer*, 1974, 34, s. 1907–1928.
- 7 Hammon, W. M. – Yohn, D. S. – Casto, B. C., et al.: Oncolytic potentials of nonhuman viruses for human cancer. I. Effects of twenty-four viruses on human cancer cell lines. *J Natl Cancer Inst*, 1963, 31, s. 329–345.
- 8 Brun, J. – Mc Manus, D. – Lefebvre, C., et al.: Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. *Molecular Therapy*, 2010, 18, s. 1440–1449.
- 9 Cawood, R. – Chen, H. H. – Carroll, F., et al.: Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. *PLoS Pathogens*, 2009, 5, s. e1000440.
- 10 Edge, R. E. – Falls, F. J. – Brown, C. W., et al.: A let-7-specific MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. *Molecular Therapy*, 2008, 16, s. 1437–1443.
- 11 Odunsi, K. – Matsuzaki, J. – Karch, J., et al.: Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. *Proceed Natl Acad Sci*, 2012, 109, s. 5797–5802.
- 12 Zhang, J. – Tai, L. H. – Ilkow, C. S., et al.: Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease. *Molecular Therapy*, 2014, 22, s. 1320–1332.
- 13 Zamarin, D. – Holmgaard, R. B. – Subudhi, S. K., et al.: Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. *Science Translational Medicine*, 2014, 6, s. 226ra32.
- 14 Kaufman, H. L. – Bines, S. D.: OPTIM trial: A Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. *Future Oncology*, 2010, 6, s. 941–949.
- 15 Adair, R. A. – Roulstone, V. – Scott, K. J., et al.: Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. *Sci Transl Med*, 2012, 4, s. 138ra77.
- 16 Phan, G. Q. – Rosenberg, S. A.: Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. *Cancer Control*, 2013, 20, s. 289–297.
- 17 Kalos, M. – Levine, B. L. – Porter, D. L., et al.: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Sci Transl Med*, 2011, 3, s. 95ra73.
- 18 Le Boeuf, F. – Batenchuk, C. – Vähä-Koskela, M., et al.: Model-based rational design of an oncolytic virus with improved therapeutic potential. *Nature Communications*, 2013, 4, s. 1974.
- 19 Kaufman, H. L. – Andtbacka, R. H. I. – Collichio, F. A., et al.: Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIb/C and IV melanoma. *J Clin Oncol*, 2014, 32, dopl. 15, 2014 ASCO Annual Meeting Abstracts, 9008a.
- 20 Din, M. O. – Danino, T. – Prindle, A., et al.: Synchronized cycles of bacterial lysis for in vivo delivery. *Nature*, 2016, 536, s. 81–85.

## Perspektivy genové terapie Alzheimerovy choroby

prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

- 1 Hardy, J. – Bogdanovic, N. – Windblad, B., et al.: Pathways to Alzheimer's disease. *Journal of Internal Medicine*, 2014, 275, s. 296–303.
- 2 Bettens, K. – Slegers, K. – Van Broeckhoven, C.: Genetic insights in Alzheimer's disease. *Lancet Neurology*, 2013, 12, s. 92–104.
- 3 Spinney, L.: Alzheimer's disease: The forgetting gene. *Nature*, 2014, 510, s. 26–28.
- 4 Lambert, J.-C., et al.: Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nature Genetics*, 2013, 45, s. 1452–1458.
- 5 Kumar, A. – Ekavali, A. S.: A review on Alzheimer's disease pathophysiology and its management: an update. *Pharmacological Reports*, 2015, 67, s. 195–203.
- 6 Karch, C. M. – Goate, A. M.: Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biological Psychiatry*, 2015, 77, s. 43–51.
- 7 Savić, N. – Schwank, G.: Advances in therapeutic CRISPR/Cas9 genome editing. *Translational Research*, 2016, 168, s. 15–21.
- 8 Alves, S. – Fol, R. – Cartier, N.: Gene therapy strategies for Alzheimer's disease: An overview. *Human Gene Therapy*, 2016, 27, s. 100–107.
- 9 Yan, R. – Vasar, R.: Targeting the  $\beta$  secretase BACE1 for Alzheimer's disease therapy. *Lancet Neurology*, 2014, 13, s. 319–329.
- 10 De Strooper, B.: Lessons from failed gamma-secretase Alzheimer trial. *Cell*, 2014, 159, s. 721–726.
- 11 Carty, N. – Nash, K. R. – Brownlow, M., et al.: Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice. *PLoS ONE*, 2013, 8, s. e59626.
- 12 Wisniewski, T. – Goni, F.: Immunotherapeutic approaches for Alzheimer's disease. *Neuron*, 2015, 85, s. 1162–1176.
- 13 Tuszyński, M. H. – Yang, J. H. – Barba, D., et al.: Nerve growth factor gene therapy. Activation of neuronal responses in Alzheimer disease. *JAMA Neurology*, 2015, 72, s. 1139–1147.
- 14 Pickford, F. – Masliah, E. – Britschgi, M., et al.: The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid  $\beta$  accumulation in mice. *J Clin Invest*, 2008, 118, s. 2190–2199.
- 15 Hudry, E. – Dashkoff, J. – Roe, A. D., et al.: Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. *Science Translational Medicine*, 2013, 5, 212ra161.
- 16 Hudry, E. – Van Dam, D. – Kulik, W., et al.: Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. *Molecular Therapy*, 2010, 18, s. 44–53.